Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03356860
Title Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE)
Acronym B-IMMUNE
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Grand Hopital de Charleroi
Age Groups: adult | senior
Covered Countries BEL

No variant requirements are available.